XML 38 R28.htm IDEA: XBRL DOCUMENT v3.25.3
Summary of Significant Accounting Policies - Segment (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
segment
Sep. 30, 2024
USD ($)
Accounting Policies [Abstract]        
Number of operating segments | segment     1  
Research And Development Expense By Major Programs [Line Items]        
Research and development $ 28,938 $ 50,723 $ 120,266 $ 172,347
Birtamimab (NEOD001)        
Research And Development Expense By Major Programs [Line Items]        
Research and development 7,136 18,159 52,483 60,908
PRX012        
Research And Development Expense By Major Programs [Line Items]        
Research and development 14,653 28,093 47,821 97,900
PRX019        
Research And Development Expense By Major Programs [Line Items]        
Research and development 2,192 1,328 6,118 2,785
Other Research And Development        
Research And Development Expense By Major Programs [Line Items]        
Research and development $ 4,957 $ 3,143 $ 13,844 $ 10,754